Empowering Lives Through Innovation and Quality Excellence
Embarking on a transformative journey over four decades, Morepen has consistently strived to embody an organization marked by discernible, impactful differences. Every action we undertake is imbued with a profound commitment to enrich the lives we touch. Nestled amidst the serene surroundings of Baddi, our cutting-edge manufacturing facility boasts a scientifically integrated complex housing 10 plants, each tailored to produce specific product lines.
Driven by a relentless pursuit of innovation, Morepen's extensive research and development infrastructure, alongside our dedicated workforce, ensures the maintenance of stringent quality standards. With a robust global footprint, we export to over 80 countries, holding certifications from esteemed regulatory authorities such as USFDA, WHO GMP, and EU GMP.
At home, our domestic offerings under the trusted brands Dr. Morepen and Gubb World span a vast array of healthcare, grooming, and OTC products, catering to the needs of over 100 million discerning consumers. As we continue to forge ahead, our unwavering commitment to quality and innovation reaffirms Morepen Laboratories as a beacon of excellence in the pharmaceutical and healthcare industry.
Know More >>
Sushil Suri, Chairman and Managing Director of Morepen Laboratories speaks to CNBC
Holistic approach towards health and wellness Core competencies of Active Pharmaceuticals Ingredient through specialized business verticals.
Morepen also holds process patents for Montelukast Sodium Amorphous in Global, USA, Canada, Europe & India.
ISO 9001:2005 and ISO 13485:2016 certification for medical devices manufacturing facility at Baddi (H.P.). This enables us as one of the largest manufacturers in point-of-care diagnostic devices in India.
Awarded Certificate of Appreciation by Pharmaceuticals export promotion council (Pharmexcil), setup by Ministry of Commerce & Industry, Government of India for 3 consecutive years.
Revenue Growth: Net revenue increased by 4% to ₹442.71 crore, up from ₹425.00 crore in Q2 FY24
EBITDA Surge: EBITDA grew by 33%, reaching ₹49.06 crore in Q2 FY25, compared to ₹36.83 crore in Q2 FY24.
Profit After Tax (PAT): PAT surged 64% to ₹34.85 crore for Q2 FY25, up from ₹21.26 crore in the same quarter last year.
Expansion in Medical Devices: The medical devices segment revenue grew by 9.35% YoY, reaching ₹133 crore. With over 13 million glucometers installed, production expansion is underway to meet growing demand.
Pharma Segment Growth: The pharma division saw a 9% revenue increase, with export revenue up by 21%, bolstered by strong performance in Europe (up 60%) and Asia.
Strategic Investment for Future Growth: Morepen raised ₹200 crore via Qualified Institutional Placement (QIP), facilitating capacity expansions across API and medical devices.
"Dr. Morepen’s devices are user-friendly, quick and reliable. With the help of these devices, we may in fact add Health to our DIY lists, instead of depending on others!”
"Dr. Morepen's device provides a clear and accurate result. Keep an instant check on your bp with the help of BP monitor by Dr. Morepen.”
Burnol a name every household trusts for quick healing of burns and cuts for more than two decades. An effective antiseptic and antibacterial topical ointment.
Lemolate Gold is a trusted medicine for cold, cough, and flu that provides superior relief without leaving you drowsy.
An alcohol-based sanitizer that thoroughly disinfects your hands while keeping them soft and leaves your hands smelling great!
BubbleChat @ Morepen is a private chat show that provides a platform for fun and engaging conversations with senior management, industry experts and mentors. The main idea behind this initiative is to foster a culture of transparency, growth and collaboration among the workforce. In order to build a more vibrant and dynamic workplace, this show is designed to bring employees closer to the higher management by engaging in meaningful discussions on various topics that impact the workplace.
